https://www.selleckchem.com/pr....oducts/carfilzomib-p
Separately, 108 individual case reports were described. Within the 424 HoFH cases, AS was identified in 57% of patients in the pre-statin era vs. 35% in patients reported more recently (2000, long-term statin period). With an increase in longevity due to statins and lipoprotein apheresis, a change in the proportion of patients with SVAS and VAS with a SVASVAS ratio of 4753 and 1090 for HoFH patients not on statin and on long-term statin, respectively, was noted. These data suggest that SVAS and VAS are frequent in HoFH an
Like
Comment
Share
